KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...

Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, patients received the agent via subcutaneous injection every three weeks ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

Stocks moved lower on Wednesday (January 14) for a second day, pulling back further from record levels, as traders digested a ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one ...